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Abstract
Pancreatic metastases from renal cell carcinoma are uncommon and their prognostic signif-
icance is not well defined. In this analysis we evaluated the outcome of patients with pancre-
atic metastases treated with either targeted therapies or local treatment to the pancreas.
Patients with pancreatic metastases from renal cell carcinoma treated between 1993 and
2014 were identified from 11 European centers. Clinical records were retrospectively
reviewed. Kaplan-Meier method and log-rank test were used to evaluate progression-free
survival and overall survival. Cox’s proportional hazard models were used for survival anal-
ysis. In total, 276 PM patients were evaluated, including 77 (28%) patients treated by either
surgery or radiotherapy to the pancreas, and 256 (93%) who received systemic therapy.
Median time from nephrectomy to diagnosis of pancreatic metastases was 91 months (IQR
54–142). Disease control rate after first-line TTs was 84%, with a median progression-free
survival of 12 months (95% CI 10–14). Median overall survival was 73 months (95% CI 61–
86) with a 5-year OS of 58%. Median OS of patients treated with local treatment was 106
months (95% CI 78–204) with a 5-year overall survival of 75%. On multivariable analysis,
nephrectomy (HR 5.31; 95%CI 2.36–11.92; p<0.0001), Memorial Sloan Kettering/Interna-
tional Metastatic RCC Database Consortium prognostic score (HR 1.45, 95% CI 0.94–2.23
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for intermediate vs good vs risk; HR 2.76 95%, CI 1.43–5.35 for poor vs good risk p =
0.0099) and pancreatic local treatment (HR 0.48; 95%CI 0.30–0.78 p = 0.0029) were asso-
ciated with overall survival. Difference in median OS between patients with PM and that
reported in a matched-control group of mRCC patients with extrapancreatic metastases
was statistically significant (p < .0001). Pancreatic metastases from renal cell carcinoma
usually occur years after nephrectomy, are associated with an indolent behavior and a pro-
longed survival. Targeted therapies and locoregional approaches are active and achieve
high disease control rate.
Introduction
RCC is the most common kidney cancer in adults [1]. Approximately 20–30% of patients with
RCC have metastases at presentation, and 30–50% will eventually develop metastatic disease
after nephrectomy [2]. The most common sites of metastases from RCC include lung, lymph
nodes, liver, bone and brain. Although PM are rare, with an incidence between 2–11% [3],
RCC represents the most common primary tumor leading to PM [4]. PM typically occur a long
time after nephrectomy and have been associated with a more favourable outcome [5–7]. Nev-
ertheless, the prognostic role of PM in patients receiving systemic treatment has not been clari-
fied. A retrospective analysis reported a longer overall survival in PM patients treated with TTs
[8]. Surgical resection of PM seems to confer a survival benefit [9] but surgery cannot always
be performed due to comorbidities or widespread disease.
The landscape of treatment for mRCC has dramatically changed with the introduction of
TTs directed against the VEGF and mTOR pathways [10–16]. Several prognostic models have
been proposed and validated to predict OS in mRCC patients including MSKCC and IMDC
criteria [17,18]. Key variables in these models include ECOG PS, time from diagnosis to initia-
tion of therapy, hemoglobin, calcium and LDH levels for MSKCC and corrected calcium, Kar-
nofsky PS, time from diagnosis to start of therapy, haemoglobin, ANC, as well as platelet
counts for the IMDC criteria.
These parameters are used to categorize patients into subgroups with good, intermediate
and poor risk of recurrence. Recently, the prognostic impact of the site of metastatic disease
such as the negative prognostic impact of bone and liver metastases in patients treated with
TTs has been proposed [19,20]. Although PM appear associated with better outcomes, specific
risk categories have not been described, and no clinical algorithm, nomogram or published risk
criteria incorporates this site of disease. Therefore, it is unclear whether the presence of PM is
an independent prognostic variable or it is dependent on other prognostic factors. Reliable
prognostic models for outcome in patients with mRCC would represent an important tool that
could be used to optimize patient selection for specific treatment strategies.
This retrospective multicenter analysis investigates clinical features and survival in a series
of consecutive mRCC patients with PM from eleven different European oncology centers, who
were treated with either TTs and/or local treatment to the pancreas.
Materials and Methods
Consecutive patient series treated at eleven European centers between 1993 and 2014 were ret-
rospectively identified from the mRCC databases of each institution based on the presence of
pancreatic metastases (data in S2 Table). Main inclusion criteria were a diagnosis of RCC of
any histological subtype, the presence of PM and a treatment for metastatic disease including
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TTs and/or locoregional approach. Patients who received prior cytokines or who were treated
with an investigational agent/combination were included, as well as those who did not receive
systemic therapy after pancreatic local treatment. The presence of other sites of disease were
allowed to study entry. Baseline demographics, clinical features, systemic treatment, prior local
treatment for pancreatic metastases, follow-up and survival data were collected by using uni-
form database templates to ensure consistent data collection. Objective assessment of tumor
changes was performed every three months by computed tomography and/or magnetic reso-
nance imaging according to single Insitutions guidelines. The RECIST version 1.0 criteria were
used to evaluate tumor response. Institutional review board approval was obtained from coor-
dinating center (Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy).
Statistical analysis
The primary outcome was OS, defined as the time from the diagnosis of PM to death for any
cause. Secondary outcomes included PFS, defined as time from the initiation of first-line TTs
to disease progression or loss to follow-up; OS calculated from the first diagnosis of metastatic
disease to death, and OS for TTs (i.e. time from initiation of first-line TTs to death). In patients
still alive at the time of the data base lock, censoring was performed at the time of last follow-
up. Furthermore, time intervals from nephrectomy to the diagnosis of PM and time from
nephrectomy to first diagnosis of metastatic disease, regardless of the site, were evaluated. The
OS of patients with PM was compared with that reported in a population of 330 consecutive
mRCC patients with extrapancreatic metastases (control group) who received TTs at Fonda-
zione IRCCS Istituto Nazionale Tumori between 2005 and 2012. A comparison between the
main clinical variables (age, prior cytokines, number of targeted therapies) and prognostic fac-
tors (ECOG PS, MSKCC prognostic score) of these two groups was performed using the chi-
square test for categorical variables, the Kruskal-Wallis test for ordinal variables and the Wil-
coxon-Mann-Whitney test for continuous variables. OS and PFS were estimated by the
Kaplan-Meier method. Potential prognostic factors for OS were investigated by using univari-
ate and multivariate Cox regression models. A p value<0.05 was considered statistically signif-
icant. All analyses were performed using SAS 9. 2 software (SAS Institute, Cary, NC, USA).
Results
Tables 1 and 2 show the characteristics of patients with PM and the control group respectively.
Despite the considerable size of the two patients cohorts, no statistically significant difference
in terms of age p = 0.585, ECOG PS p = 0.574, MSKCC score p = 0.199, prior cytokines
p = 0.900 and number of targeted therapies p = 0.109 was observed. The lack of statistical asso-
ciation for the main prognostic factors and clinical characteristics between the control group
and the group of patients with metastases to the pancreas allowed to make the two groups com-
parable, not requiring further statistical balancing methods.
In total, 276 patients with PM were evaluated. PM were synchronous to the diagnosis of the
primary in 80 cases (29%). The majority of patients (95%) had undergone nephrectomy and 99
patients (37%) received prior cytokines as first systemic treatment. Seventy-seven (28%)
patients were treated with pancreatic local treatment including surgery (89%). Forty-two
patients (15%) had isolated PM.
Median time from nephrectomy to PM diagnosis was 91 months (interquartile range, IQR,
54–142 months) and the time from nephrectomy to first diagnosis of metastatic disease was 66
months (31–122). Best response to first-line TTs was complete response in 11 cases (5%), par-
tial response in 97 cases (40%) and stable disease in 94 cases (39%), with an overall disease con-
trol rate (DCR) of 84%.
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Table 1. PM Patients characteristics (n = 276).
n %
Gender
F 97 35
M 179 65
ECOG
0
1
2
missing
Nephrectomy
No 13 5
Yes 263 95
Histology
Clear cell 263 95
Non clear cell 13 5
Fuhrman grade
1 14 6
2 134 57
3 80 34
4 6 3
missing 42
MSKCC score
Good 96 39
Intermediate 131 54
Poor 17 7
missing 32
Heng prognostic score
Good 95 44
Intermediate 112 52
Poor 8 4
missing 61
Pancreatic metastases
Synchronous 80 29
metacronous 196 71
Isolated metastatses (pancreas only metastatic site) 42 15
Sites of concomitant Metastases
Lung 129 47
Lymphnode 76 28
Liver 63 23
Bone 36 13
Kidney (contralateral) 48 18
Adrenal 34 12
Brain 17 6
Thyroid 13 5
Soft tissue 19 7
Other* 47 17
Pancreatic local treatment
Yes 77 28
(Continued)
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After a median follow-up of 36 months (95% CI 20–69 months) from the appearance of
metastatic disease, median PFS to first-line treatment was 12 months (95% CI 10–14) and
median OS calculated from PM diagnosis was 73 months (95% CI 61–86) with a 5-year OS of
58.1% (Fig 1 Overall survival calculated from PMmanifestation to death) while median OS cal-
culated from diagnosis of first metastasis to death was 95 months (95% CI 79–112) with a
5-year OS rate of 69.1%.
Median OS from the initiation of first-line TTs was 56 months (95% CI 46–67) for PM
patients (n = 199) and 23 months (95% CI 20–28) in the control group (n = 330) with a 5-year
OS rate of 48.7% and 24.9% respectively (Fig 2 Overall survival calculated from initiation of
first-line TTs for PM patients and the control group). This difference was statistically signifi-
cant (p< .0001).
Median survival according to the MSKCC risk group was 107 months (95% CI 73–136), 64
months (95% CI 45–81) and 37 months (95% CI 4–81) in patients with favorable, intermediate
and poor risk, respectively (Fig 3 Overall survival in the entire study population according to
Memorial Sloan Kettering Cancer Center prognostic risk score).
Median OS for patients who underwent pancreatic local treatment was 106 months (95% CI
78–204) with a 5-year OS rate of 75% compared with 59 months (95% CI 50–73) in patients
who did not (p< .0001) (Fig 4 Overall survival for patients who underwent pancreatic local
treatment (surgery or radiation therapy) and in those who received TTs only). No differences
in terms of MSKCC prognostic group were disclosed between patients who received only TTs
and those undergoing pancreatic local treatment (Table 3).
Within the entire patient cohort, three different subgroups were distinguished. These con-
sisted of patients having synchronous PM, patients with PM only who received locoregional
treatment and never relapsed, and patients who developed PM after first-line treatment for
metastatic disease, respectively. Among 80 (29%) patients with synchronous PM, 2 and3
TTs were administered in 28 (35%) and 22 (27%) cases, respectively. The median PFS to first-
line TTs was 10 months (95% CI 7–12) and median OS was 61 months (95% CI 33–120) with a
Table 1. (Continued)
n %
No 199 72
Type of local treatment
Surgery 68 89
Radiotherapy 6 8
Radiosurgery 2 3
missing 1
Number of targeted therapies
0 12 5
1 108 42
2 135 53
missing 21
Cytokines
Yes 99 37
No 168 63
missing 9
*Other: parotid gland, skin, ovaries, spleen, peritoneum, breast, bladder, gallbladder, pleura, heart, colon,
eye, testis, ureter, stomach
doi:10.1371/journal.pone.0151662.t001
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5-year OS of 51.3%. Twenty-five/42 patients diagnosed with isolated PM received locoregional
treatment and 17 of these patients never relapsed. Seventy-seven patients (28%) who developed
PM after first-line TTs had a median OS from PM of 67 months (95% CI 35–84) with a 5-year
OS of 53.9%.
The univariable Cox proportional regression analysis identified three prognostic factors:
MSKCC/IMDC prognostic score (intermediate vs good: HR 1.74, 95% CI 1.74–1.14; poor vs
good: HR 3.56 95% CI 1.86–6.81; p = 0.0004), nephrectomy (HR 4.44, 95% CI 2.04–9.68;
Table 2. Patient characteristics in the control group (n = 330).
n %
Gender
F 86 26
M 244 74
ECOG
0 183 56
1 129 39
2 18 5
Nephrectomy
No 42 13
Yes 288 87
Histology
Clear cell 286 87
Non clear cell 44 13
Fuhrman grade
1 15 5
2 98 30
3 127 39
4 47 14
missing 43
MSKCC score
Good 104 32
Intermediate 157 48
Poor 65 19
missing 3
Sites of Metastases
Lung 220 3
Lymph node 125 20
Liver 62 10
Bone 94 15
Thyroid 5 1
Other* 115 19
Number of targeted therapies
1 164 49
2 166 51
Cytokines
Yes 82 25
No 248 75
*Other: adrenal, soft tissue, pleural, contralateral kidney
doi:10.1371/journal.pone.0151662.t002
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Fig 1. Overall survival calculated from PMmanifestation to death.
doi:10.1371/journal.pone.0151662.g001
Fig 2. Overall survival calculated from initiation of first-line TTs for PM patients and the control group.
doi:10.1371/journal.pone.0151662.g002
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Fig 3. Overall survival in the entire study population according to Memorial Sloan Kettering Cancer Center prognostic risk score.
doi:10.1371/journal.pone.0151662.g003
Fig 4. Overall survival for patients who underwent pancreatic local treatment (surgery or radiation therapy) and in those who received TTs only.
doi:10.1371/journal.pone.0151662.g004
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p = 0.0002) and pancreatic local treatment (HR 0.42 95% CI 0.27–0.65; p<0.0001). On multi-
variable analysis MSKCC/IMDC prognostic score (intermediate vs good HR 1.45, 95% CI
0.94–2.23, poor vs good HR 2.76, 95% CI 1.43–5.35; p = 0.0099), nephrectomy (HR 5.31, 95%
CI 2.36–11.92; p<0.0001) and pancreatic local treatment (HR 0.48, 95% CI 0.30–0.78;
p = 0.0029) were confirmed as independent prognostic factors. These results were not modified
when the subgroup of patients rendered disease-free after local treatment to the pancreas was
excluded (Table 4).
Discussion
This multicentric retrospective analysis is the largest cohort of patients reported with this rare
presentation of metastatic disease treated in the era of TTs. Overall, PM are associated with
more favorable prognostic features, long response to TTs and prolonged survival.
Table 3. Outcome according to MSKCC prognostic group for patients who received only TTs and for those who received pancreatic local treat-
ment (surgery or local radiation therapy).
MSKCC prognostic group n % Median OS (months) 95% CI (range)(months) 5-year OS (%) p
Patients receiving TTs 0.255
Good 63 36 46 (37–107) 34.7
Intermediate 97 55 55 (45–70) 49.4
Poor 16 9 61 (2–70) 51.4
Patients who received pancreatic local treatment 0.377
Good 33 51 83 (65-NA) 88.2
Intermediate 31 48 106 (29–171) 66.1
Poor 1 1 - - -
doi:10.1371/journal.pone.0151662.t003
Table 4. Univariable andmultivariable Cox regression analyses of predictors of overall survival in all PM patients and excluding the subgroup of
those patients undergoing local treatment who never relapsed.
Overall PM patients
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
Nephrectomy
No vs Yes 4.44 (2.04–9.68) 0.0002 5.31 (2.36–11.92) <0.0001
MSKCC/IMDC score
intermediate vs good 1.74 (1.74–7.14) 0.0004 1.45 (0.94–2.23) 0.0099
poor vs good 2.76 (1.43–5.35)
Pancreatic local treatment
Yes vs No 0.42 (0.27–0.65) <0.0001 0.48 (0.30–0.78) 0.0029
PM patients undergoing local treatment
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
Nephrectomy
No vs Yes 4.23 (1.94–9.23) 0.0003 5.31 (2.36–11.93) <0.0001
MSKCC/IMDC score
intermediate vs good 1.67 (1.09–2.56) 0.0010 1.44 (0.93–2.22) 0.0114
poor vs good 3.33 (1.74–6.40) 2.73 (1.41–5.28)
Pancreatic local treatment
Yes vs No 0.47 (0.30–0.73) 0.0009 0.52 (0.32–0.85) 0.0092
doi:10.1371/journal.pone.0151662.t004
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RCC is a heterogeneous disease with different histological subtypes, genetic features and
clinical outcomes [21]. RCC often recurs many years after initial nephrectomy and pancreas
can be an isolated site of disease relapse associated with a more favorable outcome compared
with other metastatic sites [9,22,23]
Of interest, in the present series we observed a high number of patients with favorable prog-
nostic features such as clear cell histology (95%), prior nephrectomy (95%), metachronous
metastases (71%) and late-relapsing disease. In addition, metastatic sites usually associated
with poor outcome such as brain and bone were observed in only 6% and 13% of patients
respectively [20,24]. Moreover 15% of patients had metastases confined to the pancreas. No rel-
evant differences in terms of baseline chraracteristics between patients who received local treat-
ment to the pancreas and those who received only systemic treatment were observed. Although
the median PFS after first-line TTs was comparable with that reported in clinical trials, the
median OS appears to be almost twice longer compared to that observed in patients treated
within either clinical trials and clinical practice [25]. We observed a median time to presenta-
tion of PM after primary tumor resection of 91 months, in line with other reports, and an
impressive median OS reaching 95 months when calculated from diagnosis of metastatic dis-
ease to death and 73 months when calculated from diagnosis of PM to death, with a 5-year OS
rate of 69% and 58% respectively. Difference in OS from initiation of first-line TTs between
PM patients and the control group was statistically significant. These findings support the asso-
ciation of PM with an indolent course of disease and are consistent with evidence that the pres-
ence of PM has a favorable impact on outcome [8,26]. MSKCC risk group was associated with
OS. Other factors such as the presence of concomitant extrapancreatic metastases and ECOG
PS were not associated with outcome. On the other hand, the prognostic significance of
MSKCC risk group classification in the present cohort seems to be driven by an association
with local therapy to the pancreas in the favorable risk group while in patients treated with TTs
the differences between MSKCC subgroups were eliminated. The median OS (>5 years) in the
poor prognosis group (7%) indicates that MSKCC classification may not be relevant in this
population. Noteworthy, we observed an association of PM with other independent favorable
prognostic factors, which can account for the more favorable clinical course of this disease.
Although in a previous study we reported that PM are an independent prognostic factor [8],
the favorable prognostic role of PM remains uncertain. Whether this prognosis is the cause or
the consequence of some other favorable factors remains to be determined. A possible explana-
tion could be the long time interval from nephrectomy to the diagnosis of PM, suggesting an
extended period of dormancy of cancer cells after radical nephrectomy. This hypothesis may
justify the current practice of active surveillance as initial approach for patients with very lim-
ited disease, aimed at avoiding treatment-related toxicity and delaying the initiation of systemic
treatment whenever radiological and/or symptomatic progression is detected. Moreover,
molecular interactions between cancer cells and the pancreatic microenvironment might influ-
ence the probability that the cells will grow there (“seed and soil hypothesis”) [27]. As a result,
the tumor cells that have affinity to certain metastatic sites might harbor differences in pheno-
type that lead to peculiar patterns of growth and spread. Zerbi et al. documented favorable dis-
ease control and survival rates in patients who underwent surgery compared with nonsurgical
patients [28]. Tanis et al, reported that the 2- and 5-year OS rates were 80.6% and 72.6%,
respectively, in patients undergoing surgery, whereas they were 41% and 14% in patients who
did not undergo surgery [29]. On the other hand, Santoni et al suggested a survival advantage
for mRCC patients undergoing pancreatic surgery, although significance was not reached
probably due to the low number of patients [27]. Despite to the Tanis et al experience and simi-
larly to the Kalra et al study [30] we reported clinical data from PM patients who were mostly
treated with TTs.
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Given the heterogeneity of our study population, we evaluated the clinical outcome of three
different subgroups of patients with synchronous, metachronous and pancreatic-only metasta-
ses respectively. In the subgroup of patients presenting with metastases confined to the pan-
creas the presence of cases undergoing locoregional treatment who never relapsed may be a
confounding factor. After excluding this small subgroup of patients, both univariable and mul-
tivariable analyses were not significantly affected, and the association of nephrectomy, locore-
gional treatment and MSKCC/IMDC score with OS was confirmed. Both subgroups of
patients presenting with synchronous or metachronous PM showed an impressive median OS
evaluated from first-line TTs of 61 and 66 months respectively with a 5 years OS of more than
50%, further supporting the indolent biological behavior of PM.
In the present series, median OS was almost doubled in patients who underwent pancre-
atic local treatment, mostly surgery. Most patients undergoing local treatment had meta-
static disease confined to the pancreas and therefore seemed the ideal candidates for
pancreatic surgery leading to potential survival benefit [3,29]. Although the survival benefit
of surgery (or radiotherapy) for metastatic lesions to the pancreas could be confirmed only
in a prospective study, a randomized trial comparing surgery with conservative management
would be difficult to conduct given the rarity of this presentation and excellent long-term
survival after surgery in patients with otherwise lethal disease. Thus, retrospective series still
remain the only source of information on patients with these uncommon metastases. The
findings of the present study may serve as a basis for diversification of therapeutic strategy in
patients with PM.
Our data further confirm the efficacy of TTs in terms of OS, PFS and DCR. Response rate
was assessed in 223 patients undergoing first-line TTs, with an encouraging PFS. Treatment
strategy is long-term in these patients and at the time of treatment selection should pay special
attention to individual chronic toxicity profiles.
Only few patients developed disease progression as best response, regardless of the TTs
used. Specifically progressive disease at the initial evaluation was reported only in 9% of first-
line cases, while the median PFS was 12 months. These data could be partly explained by the
efficacy of TTs and a less aggressive disease. Although this response rate is encouraging, it
should be interpreted with caution due to the retrospective nature of the study and lack of com-
parator arm.
Other limitations of our study include the lack of central pathology or radiology review, and
the heterogeneity of patients, who were also treated with different TTs in first-, second- or sub-
sequent line settings.
Conclusions
PM usually occur many years after nephrectomy, are associated with an indolent disease course
and long-term survival. Surgery in oligometastatic disease could improve outcome. TTs are
active in this population of patients, resulting in a high DCR. Further prospective studies inves-
tigating the biological features of PM appear warranted.
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